How ligand binds to the insulin-like growth factor receptor

Yibin Xu1, Geoffrey Kong2, John Menting2, Mai Margetts2, Lauren Jenkin2, Colin Ward2, Mike Lawrence1

1Department of Medical Biology, University of Melbourne, Royal Parade, Parkville, Victoria 3050, Australia, 2Structural Biology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

E-mail: xu@wehi.edu.au

The human insulin and type 1 insulin-like growth factor receptor are homologous receptor tyrosine kinases. They are formed as disulphide-linked homodimers and share 58% sequence identity. The type 1 insulin-like growth factor receptor (IGF-1R) is involved in normal human growth and development. Aberrant IGF-1R signalling is implicated in cancer proliferation and metastasis and the receptor hence has undergone extensive investigation as a potential anti-cancer target. Insulin-like growth factor binding is understood to relax conformational restraints within the homodimer, initiating trans-phosphorylation of the receptor tyrosine kinase domains.

Our earlier crystallographic studies have focused on the insulin receptor [1]. However, there are no three-dimensional structural data for the intact IGF-1R ectodomain that might inform atomic-level understanding of how insulin-like growth factors (i.e., IGF-1 and IGF-2) bind to this receptor. To resolve these issues, we present the first and landmark crystal structures of the intact IGF-1R ectodomain—in both apo- and IGF-1 bound form, refined using data to 3.2 and 3.4 Å resolution, respectively (see images below).

In addition to providing a wealth of atomic detail, these structures lead us to suggest that the way in which ligand binds is fundamentally different to the paradigm that has been in place for a number of decades.


Keywords: IGF-1R, receptor